2024-02-10 04:27:00 ET
Summary
- Autoimmune disease biotech Kyverna Therapeutics priced above the upwardly revised range to raise $319 million at a $971 million market cap.
- As of 2/8/2024, the Renaissance IPO Index was down 3.1% year-to-date, while the S&P 500 was up 4.9%.
- Advertising contract marketplace NYIAX is tentatively scheduled for the week ahead, aiming to raise $8 million at an $82 million market cap.
Six IPOs priced this past week, joined by two blank check companies.
One larger deal did not get done: Fortegra (TFG) pulled its $297 million offering ahead of its expected pricing. The specialty insurer had previously attempted to go public in early 2021 but scrapped those plans ahead of pricing as well....
Read the full article on Seeking Alpha
For further details see:
U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week